The Prometheus League
Breaking News and Updates
- Abolition Of Work
- Ai
- Alt-right
- Alternative Medicine
- Antifa
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ascension
- Astronomy
- Atheism
- Atheist
- Atlas Shrugged
- Automation
- Ayn Rand
- Bahamas
- Bankruptcy
- Basic Income Guarantee
- Big Tech
- Bitcoin
- Black Lives Matter
- Blackjack
- Boca Chica Texas
- Brexit
- Caribbean
- Casino
- Casino Affiliate
- Cbd Oil
- Censorship
- Cf
- Chess Engines
- Childfree
- Cloning
- Cloud Computing
- Conscious Evolution
- Corona Virus
- Cosmic Heaven
- Covid-19
- Cryonics
- Cryptocurrency
- Cyberpunk
- Darwinism
- Democrat
- Designer Babies
- DNA
- Donald Trump
- Eczema
- Elon Musk
- Entheogens
- Ethical Egoism
- Eugenic Concepts
- Eugenics
- Euthanasia
- Evolution
- Extropian
- Extropianism
- Extropy
- Fake News
- Federalism
- Federalist
- Fifth Amendment
- Fifth Amendment
- Financial Independence
- First Amendment
- Fiscal Freedom
- Food Supplements
- Fourth Amendment
- Fourth Amendment
- Free Speech
- Freedom
- Freedom of Speech
- Futurism
- Futurist
- Gambling
- Gene Medicine
- Genetic Engineering
- Genome
- Germ Warfare
- Golden Rule
- Government Oppression
- Hedonism
- High Seas
- History
- Hubble Telescope
- Human Genetic Engineering
- Human Genetics
- Human Immortality
- Human Longevity
- Illuminati
- Immortality
- Immortality Medicine
- Intentional Communities
- Jacinda Ardern
- Jitsi
- Jordan Peterson
- Las Vegas
- Liberal
- Libertarian
- Libertarianism
- Liberty
- Life Extension
- Macau
- Marie Byrd Land
- Mars
- Mars Colonization
- Mars Colony
- Memetics
- Micronations
- Mind Uploading
- Minerva Reefs
- Modern Satanism
- Moon Colonization
- Nanotech
- National Vanguard
- NATO
- Neo-eugenics
- Neurohacking
- Neurotechnology
- New Utopia
- New Zealand
- Nihilism
- Nootropics
- NSA
- Oceania
- Offshore
- Olympics
- Online Casino
- Online Gambling
- Pantheism
- Personal Empowerment
- Poker
- Political Correctness
- Politically Incorrect
- Polygamy
- Populism
- Post Human
- Post Humanism
- Posthuman
- Posthumanism
- Private Islands
- Progress
- Proud Boys
- Psoriasis
- Psychedelics
- Putin
- Quantum Computing
- Quantum Physics
- Rationalism
- Republican
- Resource Based Economy
- Robotics
- Rockall
- Ron Paul
- Roulette
- Russia
- Sealand
- Seasteading
- Second Amendment
- Second Amendment
- Seychelles
- Singularitarianism
- Singularity
- Socio-economic Collapse
- Space Exploration
- Space Station
- Space Travel
- Spacex
- Sports Betting
- Sportsbook
- Superintelligence
- Survivalism
- Talmud
- Technology
- Teilhard De Charden
- Terraforming Mars
- The Singularity
- Tms
- Tor Browser
- Trance
- Transhuman
- Transhuman News
- Transhumanism
- Transhumanist
- Transtopian
- Transtopianism
- Ukraine
- Uncategorized
- Vaping
- Victimless Crimes
- Virtual Reality
- Wage Slavery
- War On Drugs
- Waveland
- Ww3
- Yahoo
- Zeitgeist Movement
-
Prometheism
-
Forbidden Fruit
-
The Evolutionary Perspective
Monthly Archives: March 2021
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer – Business Wire
Posted: March 3, 2021 at 2:05 am
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (Cyclo Therapeutics or the Company), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimers Disease, today announced the appointment of Gerald F. Cox, MD, PhD as Acting Chief Medical Officer.
Dr. Cox is an internationally renowned biotechnology executive with over 20 years of experience in drug development for rare diseases. Over the course of his career, he has made major contributions to more than 15 Investigational New Drug applications (INDs) and 6 orphan drug marketing authorizations for serious and life-threatening diseases that have generated over $5.0 billion in revenue. He brings with him extensive worldwide regulatory expertise, invaluable clinical acumen, and deep scientific insights.
As we continue to advance our Trappsol Cyclo clinical development programs, we are incredibly pleased to have secured the interest of Dr. Cox. The expertise and guidance he can provide as we execute on our clinical and regulatory strategies to treat systemic and neurologic manifestations of Niemann-Pick Type C and Alzheimers Disease will be invaluable. We look forward leveraging Gerrys breadth of knowledge and expertise to drive forward these programs as effectively and expeditiously as possible, commented, N. Scott Fine, CEO of Cyclo Therapeutics.
Dr. Cox is the founder of Gerald Cox Rare Care Consulting, LLC, where since 2018 he has been providing expert advice to small companies in all phases of clinical development for investigational rare disease drugs. From 2016-2018, Dr. Cox was the Chief Medical Officer of Editas Medicine, where he led the clinical development of CRISPR-based genome editing medicines to treat human diseases, including the first approved IND for a CRISPR-based medicine to be delivered in vivo that is designed to treat a genetic form of blindness called Leber congenital amaurosis type 10. Prior to Editas Medicine, Dr. Cox held increasingly senior roles at Genzyme (now Sanofi Genzyme) for over 15 years, advancing to Vice President of Rare Disease Clinical Development. While at Genzyme, he played an instrumental role in the global development and approval of treatments for several lysosomal storage disorders, including the enzyme replacement therapies Aldurazyme (laronidase) for Mucopolysaccharidosis type I in 2003, Elaprase (idursulfase) for Mucopolysaccharidosis type II in Japan and the Asia Pacific region in 2007, and Cerezyme (imiglucerase) for a label expansion in Gaucher disease type 3 in Australia and China in 2016, as well as the substrate reduction therapy Cerdelga (eliglustat) for Gaucher disease type 1 in 2014. He also led the early clinical development of the enzyme replacement therapies Myozyme (alglucosidase alfa) for infantile Pompe disease, which was approved in 2006, and olipudase alfa for Niemann-Pick disease type B, which recently completed a successful Phase 3 study. Dr. Cox has been affiliated with Boston Childrens Hospital during his entire career, where he is a Part-time Staff Physician in Genetics. He is also an Instructor in Pediatrics at Harvard Medical School.
Dr. Cox added, Niemann-Pick C is a devastating childhood disease for which there is no satisfactory treatment. With Cyclo Therapeutics pivotal Phase 3 study in NPC commencing next quarter and topline results from the NPC Phase 1/2 study expected in the near future, this is an exciting time for the Company. I am thrilled to be joining the Cyclo Therapeutics management team and believe they have great potential to provide potentially life-changing medicines for patients with rare diseases where there remains significant unmet need.
Dr. Cox received his MD and PhD from the University of California at San Diego and his B.A. from Harvard College. He completed an internship and residency in pediatrics followed by clinical and post-doctoral research fellowships in genetics at Boston Childrens Hospital and was Director of the Medical Genomics Mapping Facility. Dr. Cox is board-certified by the American College of Medical Genetics and Genomics in Clinical, Biochemical, and Molecular Genetics, and he was board-certified by the American Academy of Pediatrics in the past. He serves on the Board of Directors for the National Tay-Sachs and Allied Diseases organization.
About Cyclo Therapeutics
Cyclo Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families suffering from disease. The Companys Trappsol Cyclo, an orphan drug designated product in the United States and Europe, is the subject of three ongoing formal clinical trials for Niemann-Pick Disease Type C, a rare and fatal genetic disease, (ClinicalTrials.gov NCT02939547, NCT02912793 and NCT02912793). The company is planning an early phase clinical trial using Trappsol Cyclo intravenously in Alzheimers Disease based on encouraging data from an Expanded Access program for late-onset Alzheimers Disease (NCT03624842). Additional indications for the active ingredient in Trappsol Cyclo are in development. For additional information, visit the companys website: http://www.cyclotherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements about the companys current expectations about future results, performance, prospects and opportunities, including, without limitation, statements regarding the satisfaction of closing conditions relating to the offering and the anticipated use of proceeds from the offering. Statements that are not historical facts, such as anticipates, believes and expects or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the companys future performance include the companys ability to obtain additional capital to expand operations as planned, success in achieving regulatory approval for clinical protocols, enrollment of adequate numbers of patients in clinical trials, unforeseen difficulties in showing efficacy of the companys biopharmaceutical products, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing pharmaceutical grade and food products. These and other risk factors are described from time to time in the companys filings with the Securities and Exchange Commission, including, but not limited to, the companys reports on Forms 10-K and 10-Q. Unless required by law, the company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.
Read more from the original source:
Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer - Business Wire
Posted in Gene Medicine
Comments Off on Cyclo Therapeutics Appoints Gerald F. Cox, MD, PhD as Acting Chief Medical Officer – Business Wire
Entos Pharmaceuticals Partners with Alberta Cell Therapy Manufacturing and the Ottawa Hospital Research Institute to Manufacture and Ready its…
Posted: at 2:05 am
EDMONTON, AB, Feb. 25, 2021 /CNW/ -Entos Pharmaceuticals (Entos), a biotechnology company developing genetic medicines with its Fusogenix nucleic acid delivery platform, is excited to work with Alberta Cell Therapy Manufacturing and The Ottawa Hospital's Biotherapeutics Manufacturing Centre to manufacture and ready doses of Entos' made-in-Canada Covigenix VAX-001 vaccine for upcoming clinical trials at the Canadian Centre for Vaccinology.
Covigenix VAX-001 is a single-dose COVID-19 DNA vaccine that is similar to the recently approved mRNA vaccines but with the important advantages of stability at room temperature for 30 days or in the fridge for a year, and prepared in-vials at a ready-to-use concentration. In preclinical studies, Covigenix VAX-001 induced strong neutralizing antibody and durable T cell immune responses against SARS-CoV-2. Covigenix VAX-001 can be easily transported, stored, and administered for the benefit of Canadians and potentially the world. Entos received CIHR and NRC-IRAP funding for Phase 1 trial manufacturing and is actively seeking funding to advance through Phase 2 and 3 clinical trials.
Rollout of the first generation COVID-19 mRNA vaccines are underway. However, vaccine production needs to continue so enough doses are made to end the pandemic. Investing now in Canada's biotherapeutic manufacturing capacity could still produce a made-in-Canada COVID-19 vaccine. Canada could also rapidly respond to new SARS-CoV-2 variants and future pandemics and position Canada as a leader in genetic medicine.
"Finding a facility in Canada that could ready our DNA vaccine in vials time for the Phase 1 trials was extremely challenging because the few that we have here are all in high demand right now," said John Lewis, CEO of Entos Pharmaceuticals. "We were thrilled to partner with The Ottawa Hospital's Biotherapeutics Manufacturing Centre and benefit from their world-class expertise."
BMC has manufactured and readied cell, gene, and viral therapies for clinical trials for over ten years and is now instrumental in doing this for COVID-19 therapies and vaccines, including Entos' DNA vaccine. BMC also shares its world-class manufacturing and clinical trial expertise with industrial partnersand will help ACTM increase its capacity by spring 2021.
"I'm delighted that The Ottawa Hospital's Biotherapeutics Manufacturing Centre is helping to fill Canada's critical needs in COVID-19 vaccine manufacturing," said Dr. Duncan Stewart, Executive Vice-President of Research at The Ottawa Hospital and professor of medicine at the University of Ottawa. "In addition to the Entos vaccine, we will be manufacturing two other COVID-19 vaccines for clinical trials and we are already manufacturing a cell-based therapy for a COVID-19 trial. With our sustained track record of success, we are well positioned to play a key role in strengthening Canada's biotherapeutics manufacturing capacity now and into the future."
About The Ottawa Hospital's Biotherapeutics Manufacturing Centre Over the last 10 years, The Ottawa Hospital's Biotherapeutics Manufacturing Centre has successfully manufactured more than a dozen different biotherapeutics for human clinical trials in Canada and around the world, making it the most experienced facility of its kind in Canada. The Centre also leads the only hands-on training program in Canada in biotherapeutics manufacturing, in partnership with Algonquin College, the University of Ottawa and Mitacs. The Centre has been supported by the Canada Foundation for Innovation, the Ontario Research Fund, BioCanRx (a Canadian Network of Centres of Excellence) and generous donors to The Ottawa Hospital Foundation. http://www.ohri.ca/bmc.
About Alberta Cell Therapy ManufacturingLocated at the University of Alberta, ACTM offers a range of integrated services from technology transfer, process and assay development through to GMP manufacturing of products for clinical trials. The ACTM's Scientific Director Dr. Greg Korbutt and ACTM Manager Gayle Piat are excited to support the production of Ento's vaccine.With state-of-the-art equipment, a 10,000 square foot cleanroom facility and expert GMP staff, ACTM is ideally positioned to deliver biotherapeutic manufacturing services in Canada.The addition of a fill-finish suite is currently underway and will be operational in 2021. Visitwww.ualberta.ca/actm.
About Entos Pharmaceuticals, Inc.Entos develops next generation genetic therapies using their breakthrough Fusogenix nucleic acid delivery system. Fusogenix is a proteolipid vehicle (PLV) formulation that uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells. The technology is applicable to a wide range of therapeutic types including gene therapy, mRNA, miRNA, RNAi, CRISPR and small molecule drugs. Visit http://www.entospharma.com.
SOURCE Entos Pharmaceuticals
For further information: John D. Lewis, Ph.D., CEO, Entos Pharmaceuticals, Inc., Email: [emailprotected]; Jenn Ganton, Director, Communications and Public Relations, Ottawa Hospital Research Institute, Email: [emailprotected]; Greg Korbutt, Ph.D., Scientific Director, Alberta Cell Therapy Manufacturing (ACTM), Email: [emailprotected]
See the original post:
Entos Pharmaceuticals Partners with Alberta Cell Therapy Manufacturing and the Ottawa Hospital Research Institute to Manufacture and Ready its...
Posted in Gene Medicine
Comments Off on Entos Pharmaceuticals Partners with Alberta Cell Therapy Manufacturing and the Ottawa Hospital Research Institute to Manufacture and Ready its…
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results – GlobeNewswire
Posted: at 2:05 am
- Enrollment anticipated to complete in 1Q21 and topline pivotal data from the GEM-3 study of B-VEC in DEB expected in 4Q21.
- Today announced Positive Opinion from the European Medicines Agency on Orphan Drug Designation for KB407 for the treatment of cystic fibrosis.
- Strong balance sheet with December 31, 2020 ending cash, cash equivalents and short-term investments of $271.3 million. In addition, our cash position was strengthened by $151.9 million of net proceeds from 2021 subsequent offerings.
PITTSBURGH, March 01, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (Krystal) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today reported financial results and key operational progress updates for the fourth quarter ending December 31, 2020.
As the gene therapy landscape evolves, we grow increasingly confident in the unique positioning of our proprietary technology. The ability to episomally deliver therapeutic transgenes repeatedly over time has afforded us a great opportunity to develop transformative medicines for debilitating rare diseases, said Krish Krishnan, Chairman and CEO of Krystal Biotech, Inc. 2021 is an exciting year for our company as we will have Phase 3 data for B-VEC, continue to advance our rare skin pipeline, and begin dosing patients for the first time with our lung targeted vector in cystic fibrosis.
Program Highlights & Upcoming Events:
B-VEC for DEB
KB105 for TGM1-ARCI
KB407 for Cystic Fibrosis
KB301 for Aesthetic Indications
KB104 for Netherton Syndrome
Fourth Quarter and Full Year 2020 Financial Results:
Subsequent Events:
About Krystal BiotechKrystal Biotech, Inc. (NASDAQ:KRYS) is a pivotal-stage gene therapy company leveraging its novel, redosable gene therapy platform and in-house manufacturing capabilities to develop therapies to treat serious rare diseases. For more information please visit http://www.krystalbio.com.
Forward-Looking StatementsAny statements in this press release about future expectations, plans and prospects for Krystal Biotech, Inc., including but not limited to statements about the development of Krystals product candidates, such as plans for the design, conduct and timelines of ongoing clinical trials of beremagene geperpavec (B-VEC), KB105, KB104, KB301 and KB407; the clinical utility of B-VEC, KB105, KB104, KB301 and KB407, and Krystals plans for filing of regulatory approvals and efforts to bring B-VEC, KB105, KB104, KB301 and KB407 to market; the market opportunity for and the potential market acceptance of B-VEC, KB105, KB104, KB301 and KB407; plans to pursue research and development of other product candidates; the sufficiency of Krystals existing cash resources; the unanticipated impact of COVID-19 on Krystals business operations, pre-clinical activities and clinical trials; and other statements containing the words anticipate, believe, estimate, expect, intend, may, plan, predict, project, target, potential, likely, will, would, could, should, continue, and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and conduct of clinical trials, availability and timing of data from clinical trials, whether results of early clinical trials or trials will be indicative of the results of ongoing or future trials, uncertainties associated with regulatory review of clinical trials and applications for marketing approvals, the availability or commercial potential of product candidates including B-VEC, KB105, KB104, KB301 and KB407, the sufficiency of cash resources and need for additional financing and such other important factors as are set forth under the caption Risk Factors in Krystals annual and quarterly reports on file with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Krystals views as of the date of this release. Krystal anticipates that subsequent events and developments will cause its views to change. However, while Krystal may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Krystals views as of any date subsequent to the date of this release.
Source: Krystal Biotech, Inc.
Continued here:
Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results - GlobeNewswire
Posted in Gene Medicine
Comments Off on Krystal Biotech Provides Update on Operational Progress and Reports Fourth Quarter and Full Year 2020 Financial Results – GlobeNewswire
U. Cancer Center pilot projects: investigating cancer connections – The Brown Daily Herald
Posted: at 2:05 am
Eight labs who were recipients of the University Cancer Centers funding in December for projects advancing cancer research will use the funds to delve into cancer biology, cancer therapeutics and population science.
Four of the eight projects are investigating immunotherapy for gastrointestinal cancers, the tumor environments impact on cancer cell growth, the potential application of an FDA-approved Parkinsons drug to treat glioma brain tumors and the ability of a novel drug to target cancer cells that exhibit heightened aggressiveness following immunotherapy, The Herald previously reported.
The Herald spoke with three of the four other principal investigators that received grants.
Assistant Professor of Medicine Hina Khans pilot project will study the effects of blocking the antibody for chitinase 3-like-1, or CHI3L1, in advanced non-small cell lung cancer. CHI3L1 is a protein that plays an important role in tissue repair, and elevated levels of the protein indicate poor outcomes in advanced stage cancer patients. The researchers will test whether blocking the antibody a molecule that binds CHI3L1 will prevent cell resistance to immune checkpoint inhibitors in this type of lung cancer.
Assistant Professor of Medicine Olin Liang is interested in exploring womens ability to fight off leukemia and other blood diseases later in life relative to men. While the effect of aging on blood cancer development has been well-studied, not much research has gone into studying sex differences, Liang said.
Past work from the Liang lab has shown that the bone marrow environment remains healthier longer in women, leading to better blood cell production and immune response. By transplanting bone marrow stem cells from young male mice into middle-aged male and female mice, the researchers were able to compare the expression of these cells amongst the two sexes. They found higher expression in female middle-aged mice, which is indicative of a healthier bone marrow environment. This observation was due to receptors molecules that can interact with hormones to produce a response in a cell on the surface of bone marrow stem cells that were uniquely responsive to sex hormones predominantly found in women.
We have narrowed it down to two sex hormone receptors that may play a role, Liang said, referring to the receptors for follicle-timulating hormone and androgen hormone. The lab plans to use the Cancer Center pilot project funds to further study the importance of these receptors.
Using gene editing technology, the researchers plan on removing genes that code for these hormone receptors from model organisms. This step will allow them to test the effect that the loss of one or both of the receptors has on female stem cell expression levels. If the elimination of the sex hormone receptor diminishes stem cell expression, that may indicate that the receptor plays a regulatory role.
The Liang lab believes that results from these experiments will not only offer greater insight to the development of blood cancers, but also help in the formulation of sex-specific treatments. Liang hopes this research leads to treatments that enhance the male (blood cell producing) system to reduce risk of age-related blood cancer, or even other diseases.
Assistant Professor of Molecular Biology, Cell Biology and Biochemistry Mamiko Yajima studies the expression of germline molecules, which are normally only expressed during development, and how they contribute to plasticity, or the cells adaptability. Her pilot project will focus on the specific germline factor DEAD-Box Helicase 4 (DDX4), which has been found to be abnormally expressed in the tumors of certain cancers, such as small cell lung cancer and melanoma.
Yajimas lab has previously studied the expression of DDX4 in cells and organisms like sea urchins and mice. She plans to test if (DDX4) actually contributes to plasticity in the context of cancer. Yajima believes that as a germline factor, DDX4 may increase cancer cells adaptability, allowing them to develop drug resistance and migrate throughout the body more frequently.
The Yajima lab plans on using the Cancer Center funding to partner with Director of Thoracic Oncology at Rhode Island Hospital Christopher G. Azzoli and Associate Professor of Pathology and Laboratory Medicine Maria L. Garcia-Moliner to analyze DDX4 expression in cancer patient samples.
I applied for this funding with the specific goal to have access to clinical samples, Yajima said. This next stage of the project will facilitate collaboration between me, a basic biologist, and physician scientists that have the expertise to help me answer the question I want to study in a clinical setting.
To identify whether DDX4 expression correlates with patient survival, the lab will also use the funds to conduct clinical data mining of patient gene expression using the Universitys supercomputer.
Associate Professor of Dermatology and Epidemiology Eunyoung Cho studies the role of dietary factors in the development of chronic diseases. Previous work from Chos lab found that eating foods containing high levels of citrus, such as grapefruits, oranges and figs, is associated with an increased risk of skin cancer. The Cho lab plans to use the Cancer Center pilot project funds to determine the component of citrus fruit responsible for the increased risk of melanoma, the most fatal type of skin cancer.
Cho believes that furanocoumarins, a class of compounds present in high levels in citrus fruits, are what lead to the higher rates of skin cancer. These compounds can absorb ultraviolet radiation from sunlight and become activated, damaging DNA and causing mutations that can result in cancer.
To test this hypothesis, Cho has partnered with Associate Professor of Medical Science Elena Oancea, who specializes in melanoma research at the molecular level. They plan on measuring whether melanin-forming skin cells show increased levels of DNA damage when exposed to furanocoumarins and UV light.
If their data supports that furanocoumarins increase risk of cancer, this could open the door to population-based studies. Cho described one potential future direction as assessing whether furanocoumarin levels in human urine samples are indicative of melanoma risk.
Its very interesting to think about citrus fruit is something you eat all the time, Cho said. People dont understand that when you eat grapefruit (and) then go into the sunlight, you may actually increase your chance of (getting) skin cancer.
See original here:
U. Cancer Center pilot projects: investigating cancer connections - The Brown Daily Herald
Posted in Gene Medicine
Comments Off on U. Cancer Center pilot projects: investigating cancer connections – The Brown Daily Herald
Connections and inspirations between science fiction, tech, and games – VentureBeat
Posted: at 2:03 am
Join Transform 2021 for the most important themes in enterprise AI & Data. Learn more.
What happens when you put a science fiction writer, a venture capitalist, and a game journalist together? That was the premise behind our latest conversation on Oculus Venues and Zoom in a session dubbed Science Fiction, tech, and games.
I moderated the hour-long session with computer scientist and accomplished science fiction writer Ramez Naam and Tim Chang, partner at Silicon Valley venture capital firm Mayfield Fund. Chang first told me a few years ago about a virtuous cycle between the fields, where science fiction can inspire technology. Lots of firms, for instance, are trying to create Tricorder medical devices from Star Trek, and Chang himself has told entrepreneurs that if they can make the voice-driven operating system from the film Her that he would fund it.
I got the idea for the session because so much science fiction is becoming science fact. Nvidia CEO Jensen Huang has often said that were living in science fiction. Our events have harped on this theme for a few years, as things that we once thought were science fiction, like AI, have become so real in the past few years. (Well have another event, GamesBeat Summit 2021 on April 28 and April 29, to hold some similar sessions).
Before Naam started writing his Nexus trilogy (2012 to 2015) of novels, he spent 13 years at Microsoft, leading teams working on machine learning, neural networks, information retrieval, and internet-scale systems. That unique background positions him as a bridge between science fiction and technology, helping him create visions of the future tied to what is technologically possible now.
And his ideas are more relevant than ever, given the advances in AI and other digital technologies that have the potential to push us closer to a post-human future. Naam can speak to that future, as well as the possible risks that companies driving toward it may not see.
The Nexus trilogy, set in 2040, is also striking in how it foresees the political ramifications of technology. In the series, a mind-altering drug called Nexus immerses users in an augmented version of reality. The creator of Nexus is a brain-hacking civil libertarian who believes that it will free humanity and allow people to move on to a post-human future, where their minds can live on independently of their bodies.
But the U.S. government sees Nexus as an illegal drug, something that can drive a wedge between humans and enhanced humans. It wants to stamp it out and crush terrorists who plan to use it to disrupt society. Chinese researchers conduct frightening experiments that use Nexus to blend humanity and AI. Freedom-minded hackers are caught in the middle.
In addition to the Nexus series, hes written two non-fiction books: The Infinite Resource: The Power of Ideas on a Finite Planet, and More than Human: Embracing the Promise of Biological Enhancement. Naams books have earned the Prometheus, the Endeavour, the Philip K. Dick awards, been listed as an NPR Best Book of the Year, and have been shortlisted for the Arthur C. Clarke prize.
Chang heard about Naam and welcomed him on a visit to Silicon Valley in a dinner with his tech and sci-fi friends. Chang, who has twice named to the Forbes Midas List of Top Tech Investors, wanted to find startups that fit into a vision that could create a brighter outlook for humanity.
Above: Tim Chang (upper left), Ramez Naam, and Dean Takahashi.
Image Credit: Dean Takahashi
GamesBeat: How did you two meet?
Ramez Naam: Tim reached out to me on Facebook one day and said, I like your books, do you want to have dinner sometime here in the bay area? I said yes, and he set up an awesome dinner with a number of very cool people. I brought a couple of other friends as guests, some other great science fiction authors, and we hit it off immediately. Weve stayed in touch ever since.
Tim Chang: I had a hidden agenda. I was testing out this idea. I wanted to bring scientists and founders and some of my favorite science fiction authors together to see what kind of brainstorming and magic would ensue. It was fantastic. It ended up being three or four different science fiction authors, some pretty interesting folks in the science community. It was pretty inspiring to me.
Naam: People who worked in games, in neuroscience, and meditation. It was pretty good.
GamesBeat: Where did that instinct come from, Tim? Ramezs works are near-future science fiction. In that sense it seems like it makes a lot of sense that you could tap someone like that for ideas about what to fund. But what else drove that instinct?
Chang: I grew up influenced by science fiction. Its what got me into engineering, programming, and even VC. But theres a tight link between inspiration we get from science fictiontheres classic tales of many entrepreneurs who walked into VC offices back in the day with Neal Stephensons Cryptonomicon, slapping the book down and saying, I want to build this. Fund me. There are many of those inspirations.
A lot of our investment thesis ideas are fueled by near term speculative fiction, whether its Black Mirror, or my favorite, the movie Her. Ive been looking for someone to build adaptive, personalized, linear, hearable OS for years. Theres a tight virtuous cycle between science fiction, how it influences founders, scientists, the research they do, and how technology innovations and research influence authors and what they write.
And when I read Nexus, I had a suspicion this guy knows business. He knows Burning Man. He knows spirituality. He knows technology and social sciences. I was spot on. Weve been great friends ever since.
Above: Tim Chang is also friends with sci-fi writerEliot Peper. They spoke at our 2017 GamesBeat event.
Image Credit: Michael O'Donnell/VentureBeat
GamesBeat: It was clear he knew programming as well, right? Ramez, can you talk more about your background?
Naam: My first love was philosophy, but I realized there was no career to be had there. I liked physics, but I didnt want to have to be in a white lab coat my entire life. But somebody had given the school I was at, my elementary school, a Commodore VIC-20. I fell in love with programming. Its an infinite canvas. You can do whatever the heck you want.
I went to school and got a CS degree. Out of school I was lucky enough to get hired at Microsoft. I spent 13 seminal years there. I got to see and do some amazing stuff. Also, I became a burner early on. I was fascinated by what happens inside my mind. I started reading up on neuroscience. I had some friends that were neuroscientists. I would ask them, Why does this happen? And at first theyd answer questions, but after a while theyd get tired of it. Read this paper. Read this textbook.
And so to me, the whole universetheres a book called The Three Pound Universe. Everything we experience, everything we desire, all of human ingenuity, is in this little mass here. My first book, a non-fiction book, was about human augmentation, which I was massively into. Science and Nature, those journals, were my bathroom reading. I was fascinated by the things I saw going on, like rats that had electrodes that could use those in their motor cortex to control a robot arm and feed themselves. I wrote about that.
But honestly, nobody bought that book. It was well-reviewed, but it was a non-fiction pop science book. For quite a while I thought about fiction. When I finally did it, its a whole different way to reach people. You reach them on an emotional level, and you can get so much more traction to get stuff across into their minds. Thats what got me there.
GamesBeat: Tim, this whole thing he mentioned turned into the nootropic, brain enhancement or body enhancement movement. I think youve seen some of that in the VC world.
Chang: Oh yeah, yeah. It interweaves quite a bit with wearable technologies. First we had things tracking basic heart rate signals. Then it advanced to reading EEG. The first generation was reading things. Were now well into the writing aspect. You have neurostim and other things that dont just read signals, but augment them and send signals back into the body, biofeedback.
GamesBeat: Lets talk more about the Nexus trilogy. Can you summarize it quickly for us? I know that might be hard to do, but what are some of the issues that come?
Naam: Its the near future, set in 2040. The technology that people are most fixated ontheres a lot of biotech and AI and so on. But its this thing called Nexus, which is solely marketed as a party drug. Burners and ravers and whatever do it. But really its nanobots that go into your brain and attach to your neurons and broadcast and receive what theyre doing. If two of us take it and were in close proximity, our brains can start to sync up. We become telepathic.
The protagonists are San Francisco bay area grad students that are working on making it permanent, building an app layer and APIs on top of, proxying it across cell phones and the internet. You can telepathically communicate from anywhere. The real moral issue in the book is who gets control of this technology. Its all in the form of a thriller. Its a thriller with a cold war between the U.S. and China and so on. A friend of mine called it Tom Clancy meets Burning Man. I think theres more to it than that, but if you want some shorthand thats not a bad place to go.
GamesBeat: Tim, what occurred to you when you read this?
Chang: It struck me as a spiritual successor to the Matrix trilogy. I thought someone needed to pick it up and make a long form TV series out of it. Ive been bugging Ramez about this for years. Hes explained the red tape and the bureaucracy in getting fiction optioned for TV.
Naam: I explained it to Tim in venture terms. The option is the seed round. The TV show is the IPO, the big exit. Of course, to use another analogy, Netflix and Amazon and Apple TV are now adding the stack layer, easier ways to get out there. Maybe itll happen. There are people working on it right now, shopping it around in Hollywood, so someday, perhaps.
Above: Ramez Naam, science fiction writer and author of the Nexus series.
Image Credit: Ramez Naam
GamesBeat: I liked how the books spelled out the consequences of this magical invention, this brain-enhancing drug, and the relationship to AI. The politics of how different people or different countries react to the creation of thisthe U.S. has this faction that views it as an illegal drug, that the creators are terrorists who have to be stamped out, while the Chinese think its a great way to extend a single point of view or single consciousness across of the country in order to control everyone. Yet they also fear the possibility of a posthuman AI. And in the middle of all this are these hacktivists who are being hunted down and have to move underground. The politics are an interesting, more realistic part of this science fiction.
Naam: On the politics, when I started writing it, I was quite irritated about the war on drugs and the war on terror. I was writing about a technology I liked and some spiritual aspects, things like Buddhism and meditation and how technology can amplify or help us access some things in those spheres. But that political viewpoint, the question of whether government can control it or not, was on my mind as well. That led to the exercise of thinking about what will be the big geopolitical conflicts in 2040? A cold war between the U.S. and China seemed not out of the question. That became a natural tension to set up.
Hopefully things go way better in the real world compared to the politics I wrote about in the novels. The period of the last four years, the Trump presidency, was stranger and more extreme than most things Ive written about. Truth is often stranger than fiction.
GamesBeat: The other thing that happened that nobody expected was, about eight years ago, AI started working, with deep learning neural networks. The acceleration of the AI tech that, for so long, everyone had criticized as just fantasy. Thats accelerated the pace of technological change, and now it makes some of these books seem not so silly anymore, some of this science fiction.
Chang: My favorite phrase these days is, you cant make this stuff up. Its truly challenging. Fiction is feeling almost like it cant keep up with reality and some of the scenarios were running into now. Ill give an example. Black Mirror, I think it was episode one in season three, Downward Spiral, where one social reputation score affects access to rights, the ability to buy tickets. I think two months after that aired, China declared its citizen score, the black box algorithm based on loyalty to the Communist Party determining access to things like loans or buying train tickets or things like that. Youre seeing reality mirror fiction in ways that are really creepy. Reality is outpacing what weve even thought about in these ways.
The point I want to make is that Ramez does a masterful job of weaving in things like spiritual, political, cultural considerations into science fiction, which often has been a genre that doesnt do that. Id argue that its these aspects, as well as the financial and business model aspects, that are even more pertinent and important to especially near term speculative fiction and science fiction.
Naam: Important to the actual tech we develop and fund, too.
Above: Nexus is about brain enhancement. Will you take the red pill?
Image Credit: Ramez Naam
GamesBeat: You worked in machine learning for a long time. Were you surprised to see the acceleration of AI technology?
Naam: I would not say I was surprised to see that acceleration of the effectiveness of deep learning. If you look at a variety of tasks, precision and recall on a variety of things getting better over timeI didnt predict that deep learning in particular would take off. If you asked me at the time I left Microsoft, we were using two layer, three layer neural nets at the time. Boosted decision trees were still in the running. SVMs were still in the running.
Now deep neural nets have blown up in terms of their effectiveness, in part because of the incredible computational power we have, and elastic clouds where you have the luxury of being able to throw a thousand servers at something for a short period of time. And the explosion of data. Its becoming a world wheretheres been a lot of sci-fi written about inequality, but one of the big inequalities between businesses now is inequality of data. Whoever has the most and best data can train the best AI. We see this data advantage, the data virtuous cycles. Nobodys written about that, but there might be a good sci-fi concept in that.
Chang: When we were brainstorming before we were joking about, imagine the next Star Wars trilogy is about data. What would the data Death Star look like? What would data-poor rebels look like versus a data-rich empire? You could take well-known tropes from before and apply them in a new context where data, algorithms, AI, the people who understand these things are the new players in those wars.
GamesBeat: How did you feel about the fact that science fiction usually depicts AI as something that can replicate humanity, and its evil?
Naam: Honestly, in my daily life, I dont worry about sentient AI. Its a category error. The stuff were talking about as AI, machine learning, its a good categorizer. I dont know that were any closer at all to Her in a real sense, or HAL from 2001 becoming real. That said, and we can get into why if you want to, I do get annoyed with the depictions of AI in media. Not always, but usually theyre more negative. Her is a great example of a counter to that. Its also very rare for a science fiction story to be a romance. But most of the time, most depictions of AI in science fiction books, and even in moviesits going to get you. Heres a thing thats super powerful and smarter than humans and its going to eradicate us.
To start, why would it care enough to eradicate us? Maybe theres a different story, which is humans being abusive to their creations that they distrust. You saw me pivot a bit in that direction in the third book, Apex, where I posited AI as a very dangerous entity, but also showed its more human side, if you will. That was intentional.
GamesBeat: I think about some of the predictions in the books. In a lot of ways it predicted difficult political discourse that weve seen over the last four years. You had white supremacists creating a virus that they hoped would wipe out the other peoples of the world, and a crackdown or reaction to that from governments against that, and the reaction to the Nexus drug technology that followed. Im curious about the things that you think you got right, and some things that also surprised you.
Naam: I dont think reality is going to go the way of the Nexus novels necessarily. A lot of new technology that augments people, that makes us smarter, longer-lived, healthier in old age will be accepted. But the plot structure I used to motivate the world I wanted, where there was a hidden conflict, was one where this technology is heavily misused, and that causes fear. While I thinkwe dont have this tech, so its not really an issue, but I do see a huge role played by fear in politics today.
The election of Donald Trump, whats happened politically since hes been out of office, the filter bubbles are self-sorting into, fear of the other is a massively negative force in American society, and globally as well. Im curious if Tim has thoughts on that. I know youre a spiritual guy, that you care about this stuff, about creating a better world. What do we do to build different business models and different technologies that reduce fear of the other and get people to empathize and come together in some way?
Chang: Sometimes Id like to see science fiction explore more is the unintended consequences of business models and powerful technologies. Id argue weve built the real life Matrix now in our social media platforms. Not from some evil AI overlord that wants to enslave us, but because we happened to pick a business model of free ad-based revenues. Often in those cases, when its algorithmically driven and feed-based, the only conclusion is that you have to engineer a product that addicts its users. Theres no way around it.
And so even for me, as a venture capitalist, when I realized thatI told my partners, Im not going to look at business plans for social, digital media products that have free ad-based revenue models. I dont think its an ethical model. Not with the way we have to scale and grow these things. Id love to see more science fiction that explores the unintended consequences of these business models mixed with exponential technologies. Its a great way to map out what can go wrong with it.
GamesBeat: Sadly, it seems like youre going against the grain there in terms of what is popular to fund, and what turns out to be successful.
Chang: Capital seeks superior returns. Thats not always whats best aligned for the planet or for people. News, as a matter of factif it bleeds, it leads. We have to explore business models and how they form the way we wield technologies. Ive always said that tech isnt good or bad. Its a tool. What is your intention? What is the model? What is the business you wield it with?
GamesBeat: In your role at Singularity University youre focusing more on climate change and issues related to that. Is that a pivot for you as far as your interests, or did that come out of your interest in science fiction?
Naam: Within the last 10 yearsactually, the second time I quit Microsoft, my goal was to write a book about saving the world, innovating around climate and energy and so on. My agent just didnt love the book. I got stalled and didnt know what to do. I decided to write the science fiction novel. But for the last decade, parallel to the Nexus books, Ive been a forecaster, a public speaker, and sometimes an investor in clean tech, in companies trying to address climate change and other global challenges, mostly in bioenergy.
There are some similarities. Theres a science fiction aspect to looking into the future and understanding where technology can go. But mostly its just that I see it as an enormously important problem. Im not a proper VC the way Tim is, but I get people pitching me on deals all the time where I think, This could make a lot of money, but I dont see how the world would be any better. For me, it has to be addressing a real, pressing problem for humanity, aside from having the potential to be a good investment.
Climate is a hard thing. Its a very big challenge. Its a challenge that is here. Its a present danger, and it gets worse over generations. Its hard to frame it even in science fiction. A lot of science fiction talks about climate change, but you dont have a silver bullet. You cant end the story with the good guys beating the bad guys or making a discovery. Whatever it is we do, its going to be a wide portfolio or panoply of different approaches we take to de-carbonize cars, buildings, ships, planes, whatever. Itll take decades to deploy.
When I think about climate change, I think about it as a personal thing that I work on, trying to educate people and motivate people, motivate business people about where to put their money and why. But from a fiction perspective, I see it more as a backdrop to science fiction stories, rather than the core conflict or Macguffin if you will.
GamesBeat: When I think of what science fiction has become really popular in tech circles, its almost unavoidable to talk about the metaverse. Neal Stephenson coined that term way back in 1992 or so with Snow Crash. Nexus has a lot of roots in that. I wonder what you think about whether well create something like a metaverse.
Chang: Already happening. Ive seen dozens of pitches. We have successors to Second Life, which was in some ways a successor to the Well. Weve had virtual worlds for decades now. But now the headsets, the browsers, the devices are catching up to it such that we can have some pretty compelling experiences. These will continue to take off.
Again, though, you have the question. Whats your business model? Lets say your business model maximizes or incentivizes session lengths. Itll be in your interest to build a more appealing world in VR or the metaverse than the real world. Next thing you know, well have VR addiction clinics. A lot of people recently got turned on to this by Ready Player One, but that wasnt actually, to me, very future-looking. That was a love song ode to retro 80s geeks like us who grew up with those things. It was like a mixtape of past-looking greatest hits as opposed to something truly future-looking.
Naam: Theres interesting stuff in both AR and VR. As the hardware gets smaller, lighter, cheaper, longer battery life, were going to be able to do all kinds of incredible stuff. I do wondertoday its VR thats taken off more than AR. But I wonder if, as these worlds get more robust, are they going to face the same challenges that social media has? When I pull out my Oculus and put it on, a lot of whats being pitched at me is social experiences. Online, you can find a group where theyre going to amplify your opinions, whatever they are. People self-select for that, for things that amplify their existing political beliefs especially.
VR and AR have the power to be a much more emotionally impactful medium than the ones we have today. Am I going to have the Benghazi experience? An experience where Im inside the Capitol being stormed? Are those pushed to different audiences? Is that going to tear us apart even more? How do we avoid that problem? I may be overthinking it. Maybe its all going to be about exploring under the sea or going to Mars and whatnot. But I do have to wonder, given the experience of the last few years, how VR will get used and whether it will bring us together and pull us apart.
GamesBeat: I just watched a film that debuted at Sundance, A Glitch in the Matrix, from the line in the movie about how thats the only way you can tell that were living inside a computer simulation. It goes back to a 1977 speech by Philip K. Dick, another science fiction writer, about how you would be able to tell whether or not were in a simulation. The film is interesting because they found people who believe this, and theyre living their lives as if, when they walk out of a room, the simulation goes off in order to save energy. The people who were in the room talking to them, they just disappear. It feels like the logical extension of the technologies everyone is trying to create to make a believable universe. I didnt think wed see the consequences, people really believing this is true.
Naam: I dont know if its a major consequence, that people believe this is true. I think about more prosaic things, though. One of the first VR experiences I had was something called the Nantucket Project. They had VR headsets built around a stack of iPhones, and something like Google Cardboard. It wasnt the highest-end system. But it was an experience of being in a Syrian refugee camp. All you could do is turn. You were on a mostly guided tour. You couldnt walk around on your own. But you had a kid as your guide walking you through and explaining how things were, using real footage taken from this camp. It was hugely emotionally impactful. It was probably still the most emotionally impactful thing Ive done in VR.
Maybe there is room for empathy. I think it has the chance to help people see other people as real human beings. Will it get used in other ways, though? Will it get used to create hatred or sow dissent? Hopefully empathy and love willI do believe, despite the experience of the last four years, that overall more communication and higher bandwidth communication does create more connection and understanding. But thats on net. There are subsets of that communication that go the other way. Were still trying to figure out how to maximize the good.
Chang: Personally, the Planck constant is an interesting one to noodle on when it comes to the processing power of the computer simulation behind all this. But the framework I wanted to sharewe tend to, whenever theres a new platform, port things. We adapt things we knew from before to the newer platforms. Whats typically a hit, though, are things that are native to the new platform.
When the iPhone came out we ported platform games and shooters to it, but it was Angry Birds that was the first bonafide hit. It used the unique aspects of the touch interface. In VR, the first collection of content was first-person shooters and other things wed seen before. Theres a couple funny phrases Ive heard in tech. New forms of content on platforms are always the three Gs. It appeals to the most basic instincts: gambling, girls, and guns. Business models are similar. They appeal to base instincts. We say that something goes widely viral if it helps users get paid, made, or laid.
To Ramezs point, could you have other models? Thats why I led an investment in a company called Tripp. I wrote a few years ago that the most obvious thing is to go launch shooter games and Netflix 360 VR. But I wanted to see not Netflix, but net trips. Could you induce more self-discovery, more connection and empathy with others, with the self, with nature? Arguably Tripp is building one of the first digital psychedelics, a technodelic if you will, designed to shift and expand consciousness. Thats a totally different use case than what a typical game youd port to VR would focus on.
These are new categories. Theyre still in the works. But for me, there has to be a way of making ourselves better through these things.
Naam: I think its a great effort, a great thing to fund, to try to use this technology to help people modulate their emotional state, find more peace, find more tranquility, find more access to spirituality. What better use for technology is there?
GamesBeat: We have some audience questions. One of them is, how do you pop these bubbles, where people are deluding themselves? But also, how do you pop these business models that encourage them?
Naam: The question of how you pop the bubble is easier than how you pop the business model. If you look at Facebook, the feed optimizes for engagement. It optimizes for how many likes and responses a post gets. It brings you back to people who you engage with. That ends up reinforcing either positive engagements, people you mostly agree with, or sometimes it reinforces negative engagements. If I wanted to pop those filter bubbles in Facebook, Id start finding a way for the feed to surface some of the content that is not quite on your side. Maybe its not all the way on the other side. But its the best written, most reasonable, most accessible, most from people you trust, to try to spread some of that sharing of ideas.
Theres good data that social networks, whether its our personal friendships or othersthe weak connections are some of the most important ones. Theyre the ones that link one clustered network with another clustered network and bridge them together. I worry that people are just entrenching inside those clustered networks. Now, would that make Facebook more money? Maybe not in the first quarter its out there. But if I were Facebook or Twitter, Id be worried. Theyre doing well, but the platforms have become toxic enough that people are fleeing from them. Doing something to create more constructive and positive engagement below the surface, across divides, might be something that turns that around.
Chang: I totally agree with Ramez on that. A couple of vectors Ive been consideringone, back to business model. What if its not just free and ad-based? What if its tiered subscription? What if it isnt free to make a comment? What if it cost you a penny? Would it get rid of trolls immediately? This inspires the question of, do we need to redefine what free speech is in the digital era? My conclusion is theres freedom of speech in what you say, but were in an era where theres no cost or accountability to speech, especially when you can have pseudonyms or create fake accounts. Thats when you can hijack platforms and when things get dangerous. Maybe we can alleviate those with design of algorithms, feeds, feedback mechanisms, getting rid of vanity metrics like likes and retweets. But also business model choices.
The other way we could pop these bubbles, I do think the ultimate thing people want to pay for is meaning, purpose, and self-expression. If youre helping people bet on themselves, helping them be their aspirational selves, thats more like a self-improvement model, and I do think that has value. This is a silly example, but back in the day, MP3s were worth nothing, while ringtones were worth something, because ringtones were a self-expression, branding moment. That was the difference between content versus self-expression. Self-help has always proven that people want to bet on themselves, making themselves better, upgraded versions of themselves, versus downgraded, addicted versions of themselves. Thats what our current feeds and business models are designed for.
GamesBeat: We promised a bit of talk about games. I may be supposed to be bringing that in more than anyone here. Its interesting to see games drive toward increasingly realistic depictions of humans. If you think about the progress weve made with AI as well, there seems to be a lot of similar moral implications for the designers of these things. Weve talked about how social networks require some more responsible guidance or leadership. On the games side as well, were eventually going to have questions arise about whether these artificial beings were creating inside virtual worlds are ours, as property. Are they slaves? If theyre so real that they have their own consciousness, how wrong is that? I wonder what your own guidance might be in that realm as far as how designers should think about consequences.
Naam: Im not all that worried about it. Theres a world of difference between what it takes to create something that has a great facade of intelligence than something that is sentient and aware. I go back to Eliza. That was the text-based psychotherapist made in the 1970s. All Eliza was, it was a Perl script. Youd say, Im worried about my mother, and it would read those keywords and say, Tell me more about your mother. My mother is sick with diabetes. How do you feel about your mothers diabetes? Thats all it took to anthropomorphize it through a keyboard.
Even an incredible simulacrum, and theres a demand for that in gamesobviously we want great NPCs to interact with and strong storylines. Wed all love to have the digital personal assistant that organizes our lives. Doing that does not require you to solve the problem of creating consciousness. Its much easier, and it doesnt raise any ethical issues.
Chang: I get excited a lot about this topic. I wish I could do a poll of how many in the audience ever developed genuine emotions or feelings for an NPC character. I say this because I just finished about 100 hours in Cyberpunk 2077, and I noticed genuine affection for some of the love interest characters. This made me think about, could games be a vehicle for developing communications and relationship skills with others?
Imagine dialogue trees mixed with relationship coaching skills and responsive dialogue. Were going to have semantic processing that can do that. You could improve your relationship with your family or your wife someday, potentially, through these kinds of thing. It goes back to the Her analogy, from the movie, where you full-on fall in love with the operating system because it knows you better than anyone else, but it could be a possibility.
My other challenge for game designers, the ultimate opportunity is, what if you replace all the end bosses in video games with deeply spiritual reflections? The game learns you, and it turns out the big boss at the end is your own shadow side, your core wounds, your unresolved traumas. If you saw the movie Soul, from Pixar, those lost souls were just you, wrapped in the shadows of your projections and traumas and limitations. Imagine a game as a spiritual experience, or self-transformation vehicle. Thats what Id love to see.
Naam: A friend of mine is at a startup that makes software for kids with autism. They do have gamified experiences that help them understand things like, how do you read emotions? What is this person doing? Whats the right response in this situation? It seems quite effective. But the idea of just using it for ordinary adults or teenagers or whoever, anyone who wants to learn socialization skills and so on, is a good one.
Chang: Independent game developers in the art world have been doing this for a while. You have games like Papers, Please that teach you empathy for someone like a customs agent. Theyre more fringe. But you could imagine these learnings and mechanics making their way into triple-A games.
GamesBeat: I read Ready Player Two, and one of the more interesting things I thought he got right in there was that streamers will be the ones that will post their experiences of what its like to do something in a hyper-realistic virtual reality. Theyll publish these things on the equivalent of a YouTube channel, and you just step into these files and go live somebody elses experience. You could completely understand what its like to be them, whether its a transgender person or somebody living in a country far away. That was a bit of a hopeful message in that these technologies can be so immersive as to communicate to you what its like to be someone else, and that could increase empathy in the world, because its so immersive.
Chang: Do you remember a 1995 movie called Strange Days? Ralph Fiennes had this SQUID device that recorded emotional experiences. It was the ultimate spectate mode, because you could feel the emotions and sensations. Even Cyberpunk 2077 had the notion of braindance, which built on that as well. Its back to the notion of VR as an empathy engine. There will be good and there will be bad. You can imagine snuff videos and other horrifying things, but there could be beautiful things, like witnessing the birth of your baby, or falling in love. The whole range could be possible.
Naam: Maybe some of that has to do with education as well. People, when they are selecting what theyre going to go watchof course theres a lot of people who watch amazing documentaries and educate themselves and so on, but a lot more go to see action, adventure, comedy, romance, escapism. In schooling, maybe one of the things we need to have is, live a day in someone elses shoes. I think thats an amazing tool for VR or AR to help people learn. Whats it like to be of a different race, a different gender? Whats it like to live in Sri Lanka or Myanmar? To build that degree of empathy. You can combine that with things like real time speech translation and other things like that. I can imagine situations where you really increase the level of empathy.
But Im no longer quite as sure that it will all happen by itself. We have to make the intentional choice to use technology in these ways and help drive that.
Chang: Somebody told me that TikTok is kind of doing that. I have a lot of problems with TikTok and its algorithmic content, but you get authentic slices of life, five to 30 seconds at a time, from all over the world. A kid in the streets in Myanmar, something like that. That possibly is happening in these lower-res formats, which is something I hadnt expected.
GamesBeat: Theres a question for Ramez. Whats the distinction between psychedelics or drugs and technologies like virtual reality? Nexus is a drug, but it has the effect of something like taking AR glasses and putting them inside your head.
Naam: Tim should answer this one too. But theyre complementary technologies. Some thinking about psychedelic experiencethe value of putting anything in your brain whatsoever, whether its the right media that youre consuming, whether its a book, whether its Sam Delanys book Dhalgren, whos a master of science fictionthat was like a 1200 page psychedelic trip. It really was. Or its the right experience in nature or whatnot. Now, when you have AR and VR, they can do some amazing things, including psychedelic experiences. But they can probably be amplified or further amplify things that can be done with substances or meditation or other practices as well.
Theres no bright line, but there are some things that are easier to do in different ways. Its easier to give someone a very specific visual experience than a screen than it is with any drug youre going to put in your brain. Its probably easier to induce other things with something, whether its brain stimulus or molecules that interact with your brain as well. The two together might be one plus one equals three.
Chang: You could start to play with peoples perception and feed back to different senses. You could start to mix them together, simulating things like synaesthesia in virtual domains. Could you start to simulate what death is like, as you start to lose your senses? I saw one art project in VR that was used to give people a sense of what its like to be paranoid schizophrenic, by playing with the senses, overlays of things, phantom voices. You can image the empathy that can create for different neural states.
Go here to see the original:
Connections and inspirations between science fiction, tech, and games - VentureBeat
Posted in Posthuman
Comments Off on Connections and inspirations between science fiction, tech, and games – VentureBeat
Psoriasis Vs. Eczema: What’s the Difference in Symptoms and Treatments? – GoodHousekeeping.com
Posted: at 2:02 am
If you're constantly scratching dry, red patches of skin, you may be wondering if you have eczema. Depending on where that angry itch is, however, psoriasis could be your first guess. The two chronic skin conditions are distinctly different to doctors and experts who treat them, but can be very difficult to distinguish for people who are experiencing it firsthand.
They are often confused, Frank Wang, M.D., a dermatologist at Michigan Medicine at the University of Michigan, tells Good Housekeeping. They can look very similar. They both present with red patches and plaques that are scaly and can be itchy, and they can affect similar areas of the body.
With input from skin care professionals, we're helping you determine whether your skin ailment is eczema or psoriasis and tips for getting started on treatment.
Eczema isn't actually one condition all its own; the diagnosis refers to a group of skin conditions that cause itchiness, inflammation and rashes, according to the National Eczema Association (NEA). Your bout of eczema may include one of seven common conditions that affect more than 30 million Americans, including atopic dermatitis, contact dermatitis and others.
Atopic dermatitis is the most common form of eczema, Dr. Wang says. It usually starts in early childhood and features itchy rashes, most routinely on the face and in the soft spot behind the knees, that come and go.
Itchiness is the most common symptom of all types of eczema. Though, it affects people in different ways. Some only have mild itchiness, while others are so itchy that they scratch until their skin bleeds.
Other symptoms, according to the NEA, include:
Psoriasis affects about 8 million Americans, and like eczema, there are several types. The most common is called plaque psoriasis, according to the American Academy of Dermatology Association (AAD), and symptoms include:
The plaques, which can be large or small, may appear anywhere on the body but are typically on the scalp, knees, elbows and lower back.
Psoriasis can affect other parts of the body, too, including the joints, causing the condition known as psoriatic arthritis. About 30% of people with psoriasis develop psoriatic arthritis, Dr. Wang says. According to AAD, symptoms include:
Eczema and psoriasis are different chronic conditions, though they both cause red, itchy skin rashes. But for doctors, these rashes have slight differences that the trained eye can usually detect.
Atopic dermatitis tends to have less well-defined borders, doesn't have as much thick scale as psoriasis and tends to be just a little bit more crusty, Dr. Wang explains. Overall, atopic dermatitis tends to be itchier. Both are itchy conditions, but atopic dermatitis is probably more itchy.
Neither condition is contagious, and eczema and psoriasis cant be prevented.
Scientists arent sure exactly what causes eczema, but its likely genetic and triggered by allergic reactions to items like soap or fragrance, or could be onset by dry skin, Dr. Wang says. Environmental factors, like cigarette smoke, pollution and stress, could also trigger eczema, per AAD experts.
Research suggests that the immune systems in people with eczema likely overreact, causing inflammation when they come in contact with certain triggers, which makes the skin red and itchy.
Like eczema, theres no exact known cause for psoriasis, but it too has an immune system link. Psoriasis is caused by an overactive immune system that revs up the production of new skin cells. According to the National Psoriasis Foundation, skin cells typically grow and fall off within a month, but in people with psoriasis, skin cells go through this process in just a few days. Instead of falling off, the cells pile up on the skin, creating thick, scaly patches, which experts call plaques.
Eczema and psoriasis are completely different conditions. So, eczema cant turn into psoriasis, and vice versa. But, since the conditions can look so similar, it can be tough to tell the difference even in a clinical setting, especially in children. According to AAD, in these instances, a dermatologist may diagnose the skin condition as psoriasiform dermatitis.
Theres some overlap, too. Its not common, but you can technically get both psoriasis and eczema at the same time, which can be extra confusing. Your dermatologist will usually be able to distinguish between the two.
Eczema and psoriasis arent entirely curable. But, Dr. Wang says they can be treated and managed to reduce pain, control itching and minimize flare-ups of patches and plaques. Whether you're dealing with one condition or the other (or, both!), managing eczema and psoriasis starts with a skincare specialist best identifying your triggers. You'll work to avoid these irritating events, and you'll also treat any sustained skin injuries that may add to pain or irritation. Mostly, you'll work to stay out of the sun and use solutions to help avoid scratching your skin.
Mild cases of both conditions can be treated at home. Dr. Wang suggests using a mild soap, over-the-counter hydrocortisone and emollients, which are therapeutic moisturizers. There are also lotions and creams for both eczema and psoriasis available to consumers.
If your skin doesnt respond to at-home treatments, or the eczema or psoriasis exhibit more aggressive symptoms than ever before, its time to visit the dermatologist. Always discuss long-term treatment with your care provider when resorting to over-the-counter products.
Treatments will vary based on how severe the condition is and patient preference, Dr. Wang explains, but usually include topical steroids, light therapy and prescription drugs for the inflammation. For severe psoriasis, when patients have 10% to 30% of their body covered in plaques, injectable medications, called biologics, are used.
Since theres no cure, treatment and management of eczema and psoriasis will often be lifelong, Dr. Wang says. This can impact quality of life, interfere with sleep and even cause anxiety and depression; all issues that you should discuss with your primary care provider, who may refer you to additional specialists for those issues. Having a skin disorder such as eczema and psoriasis can be very emotionally and physically disabling, he says. People can feel extremely self-conscious. It can really hinder their self-confidence, and it can be very stigmatizing.
But know you're not alone, and that there are treatments that can help you.
This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io
See original here:
Psoriasis Vs. Eczema: What's the Difference in Symptoms and Treatments? - GoodHousekeeping.com
Posted in Eczema
Comments Off on Psoriasis Vs. Eczema: What’s the Difference in Symptoms and Treatments? – GoodHousekeeping.com
What causes black skin discoloration? Is it treatable? – Medical News Today
Posted: at 2:02 am
Skin discoloration can happen on any type of skin. However, it may be more apparent when it occurs on darker skin. Skin conditions, such as acne or eczema, could discolor black skin.
Many treatments can reduce skin discoloration, including laser therapy and chemical peels. Home remedies may include creams that contain vitamin C or retinol.
A person should speak with a dermatologist before trying any sort of treatment. A dermatologist specializes in treating skin conditions and can suggest a product or treatment that is a good match for an individuals skin type. A person may find a dermatologist directly, or they may receive a referral from their doctor.
Below, we look at the different causes of discoloration on black skin and how to treat it.
Discoloration on dark skin can happen for a variety of reasons, including:
Skin discoloration causes skin to look lighter (hypopigmented) or darker (hyperpigmented).
Hyperpigmentation is when the skin becomes highly pigmented and appears darker than usual. This results in dark spots.
Acne, eczema, wound healing, and sun exposure can all cause hyperpigmentation.
A form of hyperpigmentation called melasma typically occurs with hormonal changes. Pregnancy or some types of hormonal birth control could cause melasma.
Postinflammatory hyperpigmentation is common in dark skin and may develop after an injury or inflammatory response. The resulting dark spots and discoloration sometimes last for years.
With hypopigmentation, the skin loses its pigment and becomes lighter than usual. A person can be born with hypopigmentation or they can acquire it.
Like hyperpigmentation, hypopigmentation may occur once a wound heals. It is also much more noticeable on black skin.
Vitiligo is a condition that causes melanin-producing cells to malfunction, leaving some patches of skin lighter than others.
Hypopigmentation from inflammation or infection usually resolves on its own. However, hypopigmentation from scarring is more difficult to alleviate and people respond differently to vitiligo treatment.
Learn more about vitiligo here.
Causes of discoloration on the face include:
Discoloration of the hands can happen because of:
Potential reasons for discoloration on the legs include:
The American Academy of Dermatology (AAD) say that skin-lightening creams can help reduce hyperpigmentation.
However, it is advisable to buy these from a reputable retailer. Some creams may contain toxic ingredients, including mercury. Creams that do not meet stringent manufacturing safety standards may cause rashes, make discoloration worse, and exert other harmful effects on the body.
Before trying any treatment or cream, a person should either contact a dermatologist directly or speak with their doctor. A doctor may treat the condition on their own, or they may refer an individual to a dermatology department.
A person should notice their skin getting better when they stop using products that cause skin irritation and discoloration. However, it can take up to a year for some dark spots to fade.
To alleviate skin discoloration and scarring people may want to use products that contain:
Therapies that help alleviate skin discoloration include laser therapy and chemical peels.
However, a person may experience some side effects from these treatments. For example, laser therapy can help reduce dark spots but may produce hypopigmentation around the affected area. It can also worsen hyperpigmentation in some cases.
Learn more about laser therapy for scars here.
If a person notices a sudden patch of discoloration that does not go away, or gets worse, they should speak with a doctor. It is important to talk with a doctor about sudden skin discoloration as it could be a sign of skin cancer.
Similarly, if a person feels self-conscious about skin discoloration, they should talk with a dermatologist. They can suggest treatment options to reduce hypopigmentation or hyperpigmentation. A person can find a dermatologist directly or seek a referral from their doctor.
In some cases, discoloration is unavoidable.
With acne, wounds, and sunburn, some strategies can help prevent discoloration. These include:
When a person has eczema, emollients and lotions may help provide relief from itching.
While most skin discoloration is nothing to worry about, in some cases it could be a symptom of skin cancer.
According to the AAD, people of color often receive skin cancer diagnoses when their cancer is at a later stage. Because of this, it is crucial that people of color do regular skin checks.
Addressing the underlying cause of the discoloration may help reduce any future instances of hypopigmentation or hyperpigmentation. However, in some cases, hypopigmentation or hyperpigmentation can be permanent, especially if it is present at birth.
If a person has concerns about discoloration on their skin, they should speak with a dermatologist. In many cases, medical treatments may produce better results than at-home remedies. A person can contact a dermatologist directly or receive a referral from their doctor.
Skin discoloration is often harmless and not usually cause for concern. However, a person should speak with their doctor if they notice sudden changes in skin color, or the discoloration is spreading or getting worse.
See the original post here:
What causes black skin discoloration? Is it treatable? - Medical News Today
Posted in Eczema
Comments Off on What causes black skin discoloration? Is it treatable? – Medical News Today
Living with psoriasis: a patient perspective – PMLiVE
Posted: at 2:02 am
We recently spoke to Alex to get a first hand account of living with psoriasis here in the UK
My psoriasis flares up about once a month, which leaves me looking like I have third-degree burns on my face, legs, and stomach. Most of my friends dont understand it, and Im not really sure my doctor does either. Through research, and trial and error, I have learned how to manage my psoriasis, sort of. I just wish there were a magic cream out there that would make it go away for good.
We recently spoke with Alex to get a first-hand account of what its like for someone living with psoriasis in the UK, and to understand how we, as healthcare communicators, can potentially help.
Psoriasis has a profound impact on someones physical and psychological wellbeing. Flare-ups can damage confidence, limit social activity, and reduce intimacy. However, these impacts are often downplayed by those living with it.
When my psoriasis flares up I feel very self-conscious. Ive got more confident with age, but a few years ago I wouldnt wear shorts if I was having a flare-up because of how bad it looks. I would rather have an eczema flare-up than a psoriasis one. Whilst eczema hurts a lot more, it doesnt look nearly as bad, and more often than not, I can fix it.
Topical treatments are the first-line option for people living with psoriasis in the UK. The volume of available options makes it easy for people to be prescribed cream after cream, despite the fact they are having little effect on their psoriasis. Topical treatments are also expensive.
Psoriasis is a chronic condition, with little awareness amongst HCPs and the public. This can make it difficult, and often frustrating, for people living with psoriasis to continually explain their condition to others.
When I call my GP to discuss a flare up, I can hear them scrolling through all of the creams Ive had in the past. Yet they just give me another one. Ive got a drawer full of lotions and potions that do very little to make my skin better.
Alexs lotions and potions
Alexs experience is not uncommon, the majority of people find themselves being cycled through topical treatments by their GP, with little to no effect on their condition. Despite the fact that there are a number of systemic treatments now available, one studied showed that fewer than 7,000 people living with psoriasis (out of a possible 1.8 million[i]) received a biologic therapy in the UK in 2012.[ii]
Systemic treatments are typically reserved for the most severe cases. However, people with moderate/severe psoriasis can gain access to more effective treatments, if the doctor determines the impact on their life to be significant enough.
This is commonly determined by two indices, developed by theBritish Association of Dermatologists:
These indices have been around for a while, yet Alex (and many others), have little to no knowledge of their existence, or how they are used. In fact, a study revealed that only 32% of people living with psoriasis reported having their disease severity measured.[i]
Helping people understand how these tools are used by doctors, and giving them the skills to gather evidence about their condition between appointments, is an important step towards improving long-term outcomes.
There is a clear gap in understanding on both sides of the psoriasis care pathway. GPs receive little dermatology training, making it difficult for them to truly understand the impact that the condition is having on a patients life.
For those living with it, navigating a complex treatment pathway, with limited access to specialist dermatologists[ii] and whilst managing flare-ups, are significant challenges to achieving long-term goals.
Clear skin is somewhat of a perceived fantasy for most people living with psoriasis. They may have seen one or two people achieve it, but not fully understand the route taken to get there. The lack of information about how treatment decisions are made and the journey to clear skin makes it difficult for people to forge their own path there.
Having clear skin would make me confident, content, and comfortable. However, without some sort of magic cream, I dont see that it is possible. There isnt enough evidence out there.
As healthcare communicators, we have a role to play in working with the patient community to inspire the belief that achieving clear skin is possible and co-creating tools and resources to help them achieve it.
By sharing best practices, success stories, and real-life examples of others achieving clear skin, we can support the belief that clear skin is possible. We can also help to activate people living with psoriasis by focusing on three core pillars:
Activating people living with psoriasis to play a role in their treatment decisions involves three key steps:
Activating patients to take control of their health is something we at Aurora have done for our clients many times over the years. Get in touch with one of the team to find out more: piteam@auroracomms.com
[i] Psoraisis Patients Association about psoriasis. Psoriasis Patients Association 2017. Available at:https://www.psoriasis-association.org.uk/about-psoriasis Last accessed: February 2021. Last reviewed: March 2019
[ii] NICE Psoriasis Quality Standards Indicator. National Institute of Health and Care Excellence 2012. Available at:https://www.nice.org.uk/guidance/qs40/documents/psoriasis-briefing-paper2
The rest is here:
Living with psoriasis: a patient perspective - PMLiVE
Posted in Eczema
Comments Off on Living with psoriasis: a patient perspective – PMLiVE
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis -…
Posted: at 2:02 am
NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), abiopharmaceutical company, is pleased to announceit has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema.
"We believe there continues to be an unmet need for improved topical therapy for those patients suffering from mild to moderate eczema," stated Robb Knie, CEO of Hoth Therapeutics, "We are pleased with how quickly Cohort 1 of Part A of our clinical trial has reached full recruitment and we are hopeful to announce preliminary results from this trial later in the year. We are continuing our mission to bring patient focused therapies to the clinic and improve quality of life across multiple indications."
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. Hoth's pipeline development is focused to improve the quality of life for patients suffering from indications including atopic dermatitis, skin toxicities associated with cancer therapy, chronic wounds, psoriasis, asthma, acne, and pneumonia. Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19. To learn more, please visitwww.hoththerapeutics.com.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current Coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; our intellectual property; our reliance on third party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section entitled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:LR Advisors LLCEmail:investorrelations@hoththerapeutics.comwww.hoththerapeutics.comPhone: (678) 570-6791
View original content to download multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-completes-site-recruitment-for-cohort-1-of-first-in-human-clinical-trial-of-biolexa-for-the-treatment-of-atopic-dermatitis-301237720.html
SOURCE Hoth Therapeutics, Inc.
Go here to see the original:
Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis -...
Posted in Eczema
Comments Off on Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis -…
5Ws+1H: How It’s Done: Best way to combat dry skin in the cold – Tahlequah Daily Press
Posted: at 2:02 am
Cold, dry weather can present many problems to people. It can lead to garden struggles, pipe malfunctions, and all-around general discomfort.
Colder, dryer weather can also result in skin and lips becoming very dry and irritated.
The cause of this is not directly from the cold weather, but from the adverse effects cold weather brings.
Heather Winn, OSU Extension family and consumer science educator, said heating up the home is one of the causes of dry skin.
"It's not that our skin behaves differently when it is cold; it's the added lower humidity and-or the effects of heating our homes that causes our skin to be dryer in the wintertime," said Winn. "Those things, in addition to the regular conditions like bathing, soap, etc., cause the water content of our skin to be lower, with the result being dry, itchy skin."
This can also worsen the effects of already existing skin conditions, such as atopic dermatitis, better known as eczema. One of Winn's children has this condition, so she is well-versed on methods to care for dry skin.
"My youngest son has eczema, which is exacerbated during the winter months," said Winn. "We have had a lot of experience in dealing with these issues since he was a baby. If someone has super-dry skin or eczema, a wet wrap is a great way to relieve itchy dry skin."
Along with this, there are several other efficient ways to combat the itchiness and discomfort of dry skin.
"Staying hydrated is very important during cold or dry weather," said Winn.
"Take showers or baths lukewarm instead of hot. When you get out of the shower or bath, immediately put on lotion to seal in moisture from bathing."
Other ways to help dry skin include adding humidifiers to the home, continuing to wear sunscreen throughout the day, and wearing gloves when outside or in a closed area.
More here:
5Ws+1H: How It's Done: Best way to combat dry skin in the cold - Tahlequah Daily Press
Posted in Eczema
Comments Off on 5Ws+1H: How It’s Done: Best way to combat dry skin in the cold – Tahlequah Daily Press







